Screener
Candel Therapeutics, Inc. CADL Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $201.57M+100% | $194.83M+111% | $119.73M+16.6% | $86.96M+425% | $100.69M+369% | ||
| $204.16M+97.0% | $197.75M+112% | $121.39M+16.9% | $90.13M+398% | $103.61M+356% | ||
| $2M+20.7% | $2.08M+5.6% | $1.64M-25.1% | $1.36M-45.0% | $1.66M-39.0% | ||
| $208.15M+96.4% | $201.92M+111% | $125.2M+17.2% | $93.6M+335% | $105.97M+300% | ||
| $5.15M+164% | $3.04M+299% | $1.13M+376% | $1.12M+278% | $1.95M+351% | ||
| $45K— | $67K— | $89K— | —— | —— | ||
| —— | —— | $0-100% | $4.23M-57.1% | $6.7M-31.7% | ||
| $12.69M-13.8% | $7.05M-64.9% | $9M-76.0% | $10.93M-28.4% | $14.72M+5.1% | ||
| $1.09M+15.8% | $1.05M+15.8% | $1.01M+15.9% | $973K+15.8% | $939K+15.9% | ||
| $82.02M+420% | $63.89M+201% | $73.27M+80.7% | $13.47M-63.4% | $15.76M-56.8% | ||
| $761K+38.6% | $733K+48.7% | $550K+17.3% | $550K+70.8% | $549K+81.2% | ||
| -$278.15M-46.7% | -$239.25M-29.4% | -$230.39M-19.9% | -$200.89M-12.8% | -$189.62M-13.2% | ||
| $126.13M+39.8% | $138.03M+84.8% | $51.92M-21.7% | $80.12M+625% | $90.21M+1,005% | ||
| $208.15M+96.4% | $201.92M+111% | $125.2M+17.2% | $93.6M+335% | $105.97M+300% |
FAQ
- What are Candel Therapeutics, Inc.'s total assets?
- Candel Therapeutics, Inc. (CADL) holds $208.1M in total assets, up 96.4% year over year.
- How much debt does Candel Therapeutics, Inc. have?
- Candel Therapeutics, Inc. carries $2.8M in total debt against $126.1M of shareholders' equity, a debt-to-equity ratio of 0.02.
- How much cash does Candel Therapeutics, Inc. have?
- Candel Therapeutics, Inc. holds $201.6M in cash and equivalents.
- Can Candel Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 16.09 — current assets exceed current liabilities.
- Where does Candel Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Candel Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.